Topoisomerase I as a target of erlotinib and gefitinib: Efficacy of combined treatments with camptothecin

Peleg,Refael; Bobilev,Dmitri; Priel,Esther

doi:10.3892/ijo.2014.2244

Topoisomerase I as a target of erlotinib and gefitinib: Efficacy of combined treatments with camptothecin

Authors:
- Refael Peleg
- Dmitri Bobilev
- Esther Priel
View Affiliations

Affiliations: The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel, Department of Oncology, The Soroka Hospital Medical Center, Beer Sheva, Israel
Published online on: January 7, 2014 https://doi.org/10.3892/ijo.2014.2244
Pages: 934-942

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Topoisomerases are essential nuclear enzymes that work to resolve topological problems that normally occur during DNA metabolism. Their involvement in crucial DNA associated-processes, such as replication, transcription and repair, mark them as a target of chemotherapeutic drugs such as camptothecins (CPTs). Therefore, finding other agents that may alter their activity is of great importance. Previous data showed that certain tyrosine kinase antagonists, tyrphostins, inhibit the catalytic activity of the cellular topoisomerase I (topo I). We examined the effect of clinically used tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, on topo I in breast and prostate cancer cells. While erlotinib and gefitinib inhibit cellular topo I in treated cells without affecting the levels of the enzyme protein, in vitro assays show that erlotinib, but not gefitinib, inhibits the DNA relaxation activity of purified topo I. Erlotinib was found to reduce the DNA-binding ability of topo I, however, the reduction in topo I activity in gefitinib-treated cells is probably due to post-translational modifications of the enzyme protein. A combined treatment of either erlotinib or gefitinib with CPT increased the effect of CPT on the activity of cellular topo I, which supports the increased anticancer effect observed in MCF7 cells. These results suggest that topo I is a novel target of erlotinib and a combination of TKIs with topo I inhibitors may be an effective treatment for breast cancer.

View Figures

View References

1.	Cretaio E, Pattarello L, Fontebasso Y, Benedetti P and Losasso C: Human DNA topoisomerase IB: structure and functions. Ital J Biochem. 56:91–102. 2007.PubMed/NCBI
2.	Forterre P, Gribaldo S, Gadelle D and Serre M: Origin and evolution of DNA topoisomerases. Biochimie. 89:427–446. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Wang JC: DNA topoisomerases. Annu Rev Biochem. 65:635–692. 1996. View Article : Google Scholar
4.	Corbett KD and Berger JM: Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct. 33:95–118. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Tomicic MT and Kaina B: Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophysica Acta. 1835:11–27. 2013.PubMed/NCBI
6.	Haglof KJ, Popa E and Hochster HS: Recent developments in the clinical activity of topoisomerase-1 inhibitors. Cancer Ther. 1:117–145. 2006.
7.	Pommier Y: Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2053–2063. 2000.
9.	Koizumi F, Kanzawa F, Ueda Y, et al: Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (‘Iressa’) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer. 108:464–472. 2004.
10.	Chen J, Smith M, Kolinsky K, et al: Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. Cancer Chemother Pharmacol. 59:651–659. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Friedmann B, Caplin M, Hartley JA and Hochhauser D: Modulation of DNA repair in vitro after treatment with chemo-therapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res. 10:6476–6486. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Uberall I, Kolár Z, Trojanec R, Berkovcová J and Hajdúch M: The status and role of ErbB receptors in human cancer. Exp Mol Pathol. 84:79–89. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Oda K, Matsuoka Y, Funahashi A and Kitano H: A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 1:2005.0010,. 2005.PubMed/NCBI
15.	Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 11:689–708. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Smith J: Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther. 27:1513–1534. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Aflalo E, Seri I, Segal S, Gazit A and Priel E: Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action. Cancer Res. 54:5138–5142. 1994.PubMed/NCBI
18.	Bendetz-Nezer S, Gazit A and Priel E: DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Mol Pharmacol. 66:627–634. 2004.PubMed/NCBI
19.	Ciardiello F, Bianco R, Damiano V, et al: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 5:909–916. 1999.PubMed/NCBI
20.	Ueno NT and Zhang D: Targeting EGFR in triple negative breast cancer. J Cancer. 2:324–328. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Azzariti A, Xu J, Porcelli L and Paradiso A: The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol. 68:135–144. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Johnston MD, Finter NB and Young PA: Dye uptake method for assay of interferon activity. Methods Enzymol. 78:394–399. 1981. View Article : Google Scholar : PubMed/NCBI
23.	Auer B, Vosberg HP, Buhre U, Klocker H, Hirsch-Kauffmann M and Schweiger M: Intracellular distribution of DNA topoisomerase I in fibroblasts from patients with Fanconi’s anaemia. Hum Genet. 61:369–371. 1982.PubMed/NCBI
24.	Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY: 1989
25.	Kaufmann SH and Svingen PA: Immunoblot analysis and band depletion assays. Methods in Molecular Biology, DNA topoisomerase protocols: DNA Topoisomerase Protocols. Bjornsti MA and Osheroff N: 94. Humana Press Inc; Totowa, NJ: pp. 253–268. 1999, View Article : Google Scholar : PubMed/NCBI
26.	Stevnsner T, Mortensen UH, Westergaard O and Bonven BJ: Interaction between eukaryotic DNA topoisomerase I and a specific binding sequence. J Biol Chem. 264:10110–10113. 1989.PubMed/NCBI
27.	Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH and Liu LF: Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61:5926–5932. 2001.PubMed/NCBI
28.	Desai SD, Liu LF, Vazquez-Abad D and D’Arpa P: Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 272:24159–24164. 1997. View Article : Google Scholar : PubMed/NCBI
29.	Desai SD, Zhang H, Rodriguez-Bauman A, et al: Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol. 23:2341–2350. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Wang HK, Morris-Natschke SL and Lee KH: Recent advances in discovery and development of topoisomerase inhibitors as antitumor agents. Med Res Rev. 17:367–425. 1997. View Article : Google Scholar : PubMed/NCBI
31.	Pommier Y, Pourquier P, Fan Y and Strumberg D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:83–105. 1998. View Article : Google Scholar : PubMed/NCBI
32.	Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 3:430–440. 2002. View Article : Google Scholar : PubMed/NCBI
33.	Wang JC: DNA topoisomerases as targets of therapeutics: an overview. Adv Pharmacol. 29A:1–19. 1994. View Article : Google Scholar : PubMed/NCBI
34.	Baselga J, Gomez P, Awada A, et al: The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). Ann Oncol. 21(Suppl 8): 27402010.
35.	Wu X, Yalowich JC and Hasinoff BB: Cisplatin inhibits the catalytic activity of DNA topoisomerase II by binding to critical protein thiol groups and by binding to DNA. AACR Meeting: Experimental and Molecular Therapeutics 31: Topoisomerase, Telomerase, and Nucleosides/Nucleotides. Abst. 3079,. 2004
36.	Aoe K, Kiura K, Ueoka H, et al: Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. Anticancer Res. 24:3893–3897. 2004.PubMed/NCBI
37.	Camp ER, Summy J, Bauer TW, Liu W, Gallick GE and Ellis LM: Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res. 11:397–405. 2005.PubMed/NCBI
38.	Chen YJ: Mechanisms underlying resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer. Biol Biomed Rep. 2:141–148. 2012.
39.	Chen YJ, Huang WC, Wei YL, et al: Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 6:e214282011. View Article : Google Scholar : PubMed/NCBI
40.	Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 284:31–53. 2003. View Article : Google Scholar : PubMed/NCBI
41.	Kim H, Kim SH, Kim MJ, et al: EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother. 34:372–381. 2011. View Article : Google Scholar : PubMed/NCBI
42.	Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK and Perez-Soler R: Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27^KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol. 72:248–258. 2007. View Article : Google Scholar : PubMed/NCBI
43.	Li Z, Xu M, Xing S, et al: Erlotinib effectively inhibits JAK2^V617F activity and polycythemia vera cell growth. J Biol Chem. 282:3428–3432. 2007. View Article : Google Scholar : PubMed/NCBI
44.	Shi Z, Peng XX, Kim IW, et al: Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67:11012–11020. 2007. View Article : Google Scholar : PubMed/NCBI
45.	Yang CH, Huang CJ, Yang CS, et al: Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res. 65:6943–6949. 2005. View Article : Google Scholar
46.	Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y and Sugimoto Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther. 3:1119–1125. 2004.PubMed/NCBI
47.	Marchetti S, de Vries NA, Buckle T, et al: Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1^−/−/Mdr1a/1b^−/− (triple-knockout) and wild-type mice. Mol Cancer Ther. 7:2280–2287. 2008. View Article : Google Scholar : PubMed/NCBI
48.	Normanno N, Maiello MR and De Luca A: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol. 194:13–19. 2002. View Article : Google Scholar : PubMed/NCBI